Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F A Spencer

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Journal of Thrombosis and Thrombolysis|December 10, 1999
Key references: Antiphospholipid antibody syndromeF A Spencer
Journal of Thrombosis and Thrombolysis|January 13, 2001
Heparin-induced thrombocytopenia: patient profiles and clinical manifestationsF A Spencer
Postgraduate Medicine|October 1, 1985
Personalized care still physicians dutyF A Spencer
Journal of Thrombosis and Thrombolysis|December 10, 1999
Key references: Protein C, protein S, and antithrombin deficienciesF A Spencer
Journal of Thrombosis and Haemostasis : JTH|January 12, 2010
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleedingS Schulman, F A Spencer
Journal of Thrombosis and Thrombolysis|June 12, 1999
Diagnosis and management of inherited and acquired thrombophiliasF A Spencer, R C Becker
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
Asymptomatic thrombophilia--a family affairF A Spencer, R J Goldberg
Current Cardiology Reports|September 12, 2000
Novel inhibitors of factor X for use in cardiovascular diseasesF A Spencer, R C Becker
Journal of Thrombosis and Thrombolysis|May 1, 2002
Low molecular weight heparin and unfractionated heparin in the early pharmacologic management of acute coronary syndromes: a meta-analysis of randomized clinical trialsM T Le Nguyen, F A Spencer
American Heart Journal|August 2, 2001
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibitionY F Li, F A Spencer, R C Becker
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Journal of Thrombosis and Thrombolysis|December 10, 1999
Key references: Antiphospholipid antibody syndromeF A Spencer
Journal of Thrombosis and Thrombolysis|January 13, 2001
Heparin-induced thrombocytopenia: patient profiles and clinical manifestationsF A Spencer
Postgraduate Medicine|October 1, 1985
Personalized care still physicians dutyF A Spencer
Journal of Thrombosis and Thrombolysis|December 10, 1999
Key references: Protein C, protein S, and antithrombin deficienciesF A Spencer
Journal of Thrombosis and Haemostasis : JTH|January 12, 2010
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleedingS Schulman, F A Spencer
Journal of Thrombosis and Thrombolysis|June 12, 1999
Diagnosis and management of inherited and acquired thrombophiliasF A Spencer, R C Becker
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
Asymptomatic thrombophilia--a family affairF A Spencer, R J Goldberg
Current Cardiology Reports|September 12, 2000
Novel inhibitors of factor X for use in cardiovascular diseasesF A Spencer, R C Becker
Journal of Thrombosis and Thrombolysis|May 1, 2002
Low molecular weight heparin and unfractionated heparin in the early pharmacologic management of acute coronary syndromes: a meta-analysis of randomized clinical trialsM T Le Nguyen, F A Spencer
American Heart Journal|August 2, 2001
Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibitionY F Li, F A Spencer, R C Becker
Pageof 4